Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...
Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its late-stage candidate for metabolic dysfunction-associated steatohepatitis (MASH). The $14.50-per-share deal ...
Woman's World on MSN
What Did 'M*A*S*H' Movie Director Robert Altman Think of the TV Show?
The classic comedy M*A*S*H had one of the most impressive runs of any TV series. The show, which starred Alan Alda and Wayne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback